Table 1. Patient summary.
| Patient | Dose level | Gender | Age (years) | Clinical outcome |
|---|---|---|---|---|
| 1 | 1 | F | 51 | Excellent response to treatment, had nine cycles |
| 2 | 1 | F | 62 | PD after C2 |
| 3 | 1 | F | 57 | PD after C4 |
| 4 | 2 | M | 31 | Withdrawn due to brain metastases |
| 5 | 2 | F | 41 | Improvement in CT after C3, but PD after C5 |
| 6 | 2 | M | 55 | PD after 22 days |
| 7 | 2 | M | 37 | After C6, MRI revealed cysts and no cancer |
| 8 | 3 | M | 55 | PD after 31 days |
| 9 | 3 | M | 52 | PD after C2 |
| 10 | 4 | F | 50 | Minor response after C3. Withdrawn due to G4 thrombocytopenia after C4 |
| 11 | 4 | F | 52 | Stopped after C2 due to haematoxocity and allergic reaction to taxol |
| 12 | 4 | F | 66 | PD after C3 |
| 201 | 4 | M | 65 | PD after C2 |
| 13 | 4 | F | 38 | Withdrawn due to brain metastases after C3 |
| 14 | 4 | M | 29 | Not given treatment, bleeding lesion |
| 202 | 4 | M | 53 | PD after C2 |
| 203 | 5 | M | 68 | Withdrawn due to brain metastases after C1 |
| 204 | 5 | M | 63 | SD after C2 and C4, but withdrawn due to brain metastases after C4 |
| 205 | 5 | M | 54 | Withdrawn due to brain metastases after C1 |
| 206 | 6 | F | 52 | PR after C3, had six cycles in total |
| 20 | 6 | M | 41 | PD after C2 |
| 21 | 6 | M | 69 | PD after C2 |
Patients were recruited at two centres, with different patient number schemes at each center.
PD=progressive disease; C2=course 2, etc.; CT=computerised tomography scan; MRI=magnetic resonance imaging scan; G4=Grade 4, etc., M=male; F=female; PR=partial response; SD=stable disease.